Novel Tests

Explore our research into novel biomarker testing

Mesothelin

Mesothelin is a cell-surface protein expressed by mesothelial cells. Mesothelial cells form a protective lining called the mesothelium, which surrounds the lungs, abdominal cavity, heart, and other internal organs. A soluble form can be measured in the blood and may serve as a marker of mesothelial injury.

Mesothelin

Why Mesothelin matters

Mesothelin measurement may have important diagnostic and prognostic value in cancer, particularly mesothelioma and ovarian cancer. Mesothelioma is a cancer that develops in the mesothelium, most often in the pleural mesothelium surrounding the lungs, and is usually linked to asbestos exposure. Elevated mesothelin levels may help distinguish mesothelioma from benign pleural conditions and may also be useful for monitoring disease progression. In ovarian cancer, mesothelin may support diagnosis and provide prognostic information, particularly when combined with CA 125. In non-malignant disease, mesothelin may be an indicator of mesothelial injury, particularly injury related to asbestos exposure.

Ready To Transform Your Laboratory Services?

Elevate your healthcare provider experience. Speak with us today to discuss your health service needs.

Book A Call Today Drop Us A Message

More Novel Tests

Amphiregulin

arrow_forward_ios

Heparin-Binding EGF-Like Growth Factor (HB-EGF)

arrow_forward_ios

Transforming Growth Factor Alpha (TGF-α)

arrow_forward_ios

Dickkopf-1 (DKK-1)

arrow_forward_ios

Programmed Cell Death Protein 1 (PD-1)

arrow_forward_ios

Soluble Receptor for Advanced Glycation End Products (sRAGE)

arrow_forward_ios

Galectin-3

arrow_forward_ios

Monomeric CRP (mCRP)

arrow_forward_ios

Interleukin-18 (IL-18)

arrow_forward_ios

Free PSA Isoforms

arrow_forward_ios

References

Argani, P. (2001). Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clinical cancer research, 3862-3868.Bostancı, Ö. (2014). Preoperative serum levels of mesothelin in patients with colon cancer. Disease Markers, 161954.Chang, K. I. (1992). Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. International journal of cancer, 373-381.Cristaudo, A. F. (2007). Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clinical Cancer Research, 5076-5081.Cui, A. e. (2014). Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis. BMJ open, e004145.Einama, T. (2016). Clinical impacts of mesothelin expression in gastrointestinal carcinomas. World Journal of Gastrointestinal Pathophysiology, 218.Grigoriu, B. (2007). Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clinical Cancer Research, 2928-2935.Hassan, R. (2006). Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clinical cancer research, 447-453.Hollevoet, K. (2012). Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual ptient data meta-analysis. Journal of Clinical Oncology, 1541-1549.Huang, C. (2006). Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. Anticancer research, 4721-4728.Li, S. (2017). Plasma mesothelin as a novel diagnostic and prognostic biomarker in colorectal cancer. Journal of Cancer, 1355.Lv, J. (2019). Mesothelin as a biomarker for targeted therapy. Biomarker Research, 1-18.Pass, H. I. (2008). Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. The Annals of thoracic surgery, 265-272.Rai, A. J. (2010). Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels. Clinical Chemistry and Laboratory Medicine, 271-278.Robinson, B. W. (2003). Mesothelin-family proteins and diagnosis of mesothelioma. The Lancet, 1612-1616.Robinson, B. W. (2005). Soluble mesothelin-related protein--a blood test for mesothelioma. Lung Cancer, S109-S111.Saha, S. (2023). High expression of mesothelin in plasma and tissue is associated with poor prognosis and promotes invasion and metastasis in gastric cancer. Advances in Cancer Biology-Metastasis, 100098.Sharon, E. (2012). Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers. Clinical chemistry and laboratory medicine, 721-725.Yu, M. (2015). Mesothelin (MSLN) methylation and soluble mesothelin-related protein levels in a Chinese asbestos-exposed population. Environmental Health and Preventive Medicine, 369-378.